title: Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: a case report and review of the literature.
abstract: Hemolytic uremic syndrome (HUS) is a rare thrombotic complication characterized by a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS may be caused by several different conditions, including infection, malignancy, and chemotherapeutic agents, such as mitomycin, cisplatin, and most recently, gemcitabine. The outcome of gemcitabine-induced HUS is poor, and the disease has a high mortality rate. This study reports a case of gemcitabine-induced HUS in a patient with pancreatic cancer in Korea.
authors: Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
authors: Hye Won
authors: HW
authors: Lee
authors: Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
authors: Moon Jae
authors: MJ
authors: Chung
authors: Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
authors: Huapyong
authors: H
authors: Kang
authors: Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
authors: Heun
authors: H
authors: Choi
authors: Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
authors: Youn Jeong
authors: YJ
authors: Choi
authors: Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
authors: Kyung Joo
authors: KJ
authors: Lee
authors: Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
authors: Seung Woo
authors: SW
authors: Lee
authors: Division of Nephrology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
authors: Seung Hyuk
authors: SH
authors: Han
authors: Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
authors: Jin Seok
authors: JS
authors: Kim
authors: Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
authors: Si Young
authors: SY
authors: Song
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives*; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine
keywords: Gemcitabine; Hemolytic-uremic syndrome; Pancreatic neoplasms